Evidence map›Paper›PMID 39639166›Full record

ArticleCommunications medicine2024

Transplantation of decellularized porcine kidney grafts repopulated with primary human cells demonstrates filtration function in pigs.

David Y Lo, Boyukkhanim Ahmadzada, MacKenna A Stachel, Melia Schaefer, Usman Ashraf, John I Wagner, Ethan J Vanderslice, Madie Tornquist, Kendra Mariakis, Peggy Halsten and 4 more

Abstract read
In one paragraph

Article in Communications medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Decellularized rat tubules for tissue engineering.Translational andrology and urology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

David Y LoMiromatrix Medical Inc. a Subsidiary of United Therapeutics Corporation, Eden Prairie, MN, USA. dlo@miromatrix.com.
Boyukkhanim AhmadzadaDepartment of Surgery, Mayo Clinic, Rochester, MN, USA.
MacKenna A StachelMiromatrix Medical Inc. a Subsidiary of United Therapeutics Corporation, Eden Prairie, MN, USA.
Melia SchaeferMiromatrix Medical Inc. a Subsidiary of United Therapeutics Corporation, Eden Prairie, MN, USA.
Usman AshrafMiromatrix Medical Inc. a Subsidiary of United Therapeutics Corporation, Eden Prairie, MN, USA.
John I WagnerMiromatrix Medical Inc. a Subsidiary of United Therapeutics Corporation, Eden Prairie, MN, USA.
Ethan J VandersliceMiromatrix Medical Inc. a Subsidiary of United Therapeutics Corporation, Eden Prairie, MN, USA.ORCID http://orcid.org/0000-0002-6273-921X
Madie TornquistMiromatrix Medical Inc. a Subsidiary of United Therapeutics Corporation, Eden Prairie, MN, USA.
Kendra MariakisMiromatrix Medical Inc. a Subsidiary of United Therapeutics Corporation, Eden Prairie, MN, USA.
Peggy HalstenMiromatrix Medical Inc. a Subsidiary of United Therapeutics Corporation, Eden Prairie, MN, USA.
Christopher D LindsayMiromatrix Medical Inc. a Subsidiary of United Therapeutics Corporation, Eden Prairie, MN, USA.
Emily C BeckMiromatrix Medical Inc. a Subsidiary of United Therapeutics Corporation, Eden Prairie, MN, USA.
Scott L NybergDepartment of Surgery, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0002-5005-3050
Jeffrey J RossMiromatrix Medical Inc. a Subsidiary of United Therapeutics Corporation, Eden Prairie, MN, USA. JRoss@miromatrix.com.ORCID http://orcid.org/0009-0000-6282-2059

Funding

Immunodeficient FAH-/- PigsR01DK106667 · NIDDK · MAYO CLINIC ROCHESTER · PI NYBERG, SCOTT L · 2015 to 2019
$2.1M
NIDDK NIH HHS R01 DK106667
6 · The paper itself

Abstract

backgroundEnd-stage renal disease is a growing global health issue, disproportionately impacting low- and middle-income countries. While kidney transplantation remains the best treatment for end-stage renal disease, access to this treatment modality is limited by chronic donor organ shortages. To address this critical need, we are developing transplantable bioengineered kidney grafts.

methodsPodocyte differentiation was achieved in adherent monoculture through Wnt and TGF-β inhibition with IWR-1 and SB431542, respectively. Podocytes along with endothelial cells were then used to recapitulate glomeruli within decellularized porcine kidney scaffolds to generate bioengineered kidneys grafts. These bioengineered kidney grafts were functionally assessed via normothermic perfusion which compared kidney grafts recellularized with only endothelial cells as a control to bi-culture kidney grafts comprised of endothelial cells and podocytes. Heterotopic implantation further tested bi-culture kidney graft function over 3 successive implant sessions with 1-2 grafts per session.

resultsWe demonstrate the ability to source primary human podocytes at scale. Decellularized porcine kidney grafts repopulated with podocytes and endothelial cells exhibit native glomerular structure and display blood filtration capabilities during normothermic perfusion testing. Extending these findings to a clinically relevant model, bioengineered kidneys produce urine with indices of filtration when heterotopically implanted in pigs.

conclusionsOur results showcase a human-scale, transplantable bioengineered kidney capable of performing requisite filtration function. This study reinforces the possibility for the bioengineering of transplantable human kidneys, which could someday provide increased and more equitable access to kidney grafts for the treatment of end-stage renal disease.

Identifiers

PMID39639166
PMCPMC11621697

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.